OCDX

ANALYST NOTE: ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC (OCDX) DATE: 2026-06-13 CURRENT PRICE: $17.63

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 2.6% (Productive)

Analysis:

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None identified at this date.

There is no named secular thesis attached to OCDX as of 2026-06-13. The investment case is not driven by a macro narrative (e.g., "post-pandemic diagnostic normalization" or "AI-driven lab automation") but is strictly a function of setup quality and business fundamentals. As a tactical, setup-led name, the conviction must be derived entirely from the structural readiness of the chart (which is currently absent) and the strength of the underlying business metrics available in the evidence base. No thesis is invented; the name is judged on its operational reality and the absence of a confirmed technical breakout.

3. Business Analysis

Company Profile: Ortho Clinical Diagnostics Holdings plc (OCDX) is a global provider of in-vitro diagnostic solutions, established in 1939 and headquartered in Raritan, New Jersey. The company operates in the Medical Devices / Diagnostics industry, serving both clinical laboratories and the transfusion medicine community.

Business Model & Operations: The company generates revenue through a comprehensive portfolio of automated instruments, assays, reagents, and consumables.

• Core Offerings: The portfolio includes clinical chemistry and immunoassay systems for disease detection and tracking. It also provides immunohematology instruments for blood typing and donor screening, alongside contract manufacturing and "orthocare" services.
• Market Reach: As of the latest available data, the company's products and technologies are utilized by over 800,000 patients.
• Revenue Drivers:
• Transfusion Medicine: This segment demonstrated strong growth, up 11%, driven by immunohematology and donor screening businesses.
• Core Revenue: Excluding COVID assay revenue, core revenue grew slightly over 4% in constant currency.
• Geographic Growth: Management expects China to grow at high single or low double-digits for the year.

Supply Chain & Operational Constraints (Historical Context): While the current date is 2026, the evidence base provided contains specific operational data from the 2022 earnings transcript (2022-05-07) which remains the only quantitative evidence of supply chain dynamics available in this dataset.

• Instrument Placement: In the referenced period, the company ended a quarter with approximately 600 open orders for instruments due to semiconductor chip and supply chain challenges.
• Growth Impact: Management stated that had these orders shipped, total installed growth would have been closer to 5%, and revenue growth would have been 2 to 3 percentage points higher.
• Margin Headwinds: Management noted that full-year adjusted free cash flow was expected to be negatively affected by approximately $20 million, including a 150 basis point headwind on adjusted EBITDA margin due to increased cost of materials.

*Note: As of 2026-06-13, there is no evidence in the provided block confirming whether these supply chain constraints have been resolved or if the $20 million headwind has been fully absorbed. The business description relies on the 2022 operational baseline.*

4. Archetype and Conviction

Archetype Candidate: — Classification: Unable to classify.

Without a defined setup (Forming/Confirmed) or recent financial data post-2022 to confirm a turnaround or growth acceleration, OCDX cannot be assigned a specific archetype (e.g., Margin Inflector, Deep Value Recovery) with certainty.

Conviction Stack:

• Thesis Strength: Low (No named secular thesis; purely tactical).
• Evidence Quality: Mixed. The evidence base is heavily weighted toward 2022 operational data (supply chain constraints, specific growth rates) and general company profile data. There is a lack of 2023–2026 financial performance data to confirm if the "core revenue growth" and "transfusion medicine strength" have persisted or accelerated.
• Setup Readiness: None. The setup is not actionable.
• Rerating Potential: Unknown. Without a confirmed breakout or a clear narrative of margin expansion (beyond the 2022 headwinds), rerating potential cannot be quantified.

ATR Context: The current ATR of 2.6% is "productive" but sits below the historical "sweet spot" of 4–6% for high-conviction breakouts. This suggests the stock is not currently exhibiting the volatility typically associated with a major structural move, further supporting the "context-only" classification.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: If the company fails to resolve the supply chain issues noted in 2022 (or if new ones arise) leading to a decline in instrument placements, or if core revenue growth stalls below the 4% baseline, the fundamental thesis weakens.

What Would Strengthen the Case:

• Fundamental: Confirmation that the 600 open orders from 2022 were successfully shipped and that the 150 bps margin headwind has been reversed, leading to EBITDA expansion.

Gaps in Evidence Base:

• Missing Financials: There is no evidence for the years 2023, 2024, 2025, or 2026. The most recent earnings data is from May 2022.
• Missing Guidance: No management guidance or capex plans are available for the 2026 period.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key risks: Lack of recent financial data to confirm if 2022 supply chain issues are resolved; No secular thesis to support a tactical entry; Volatility is too low to suggest an imminent structural move. Expected path: The stock will likely remain in a consolidation or trend-following mode until a structural setup forms or new financial data clarifies the post-2022 operational status. Expected horizon: Indefinite until setup formation or new earnings release. Failure mode to watch: A close below any potential support level (if one were to form) or a continued lack of fundamental catalysts to justify a position.